COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,582 Articles (22,415 medRxiv, 8,167 bioRxiv)

Most recent first Previous |  Page 532: Articles 5311-5320  | Next

The humoral and cellular immune response of a third dose adenoviral-based vectored vaccine after a single or 2 shots of inactivated COVID-19 vaccine in healthy adults.
Suparak, S., Bumroongthai, K., Jantapalaboon, D., Phairoh, P., Wongkidakarn, S., Yodtup, C., Puangtubtim, W., Pimpapai, W., Soonthornchattrawat, S., Dhepaksorn, P., Mahasirimongkol, S.
10.1101/2022.10.18.512323 — Posted: 2022-10-19
Impact of SARS-CoV-2 ORF6 and its variant polymorphisms on host responses and viral pathogenesis.
Kehrer, T., Cupic, A., Ye, C., Yildiz, S., Bouhhadou, M., Crossland, N. A., Barrall, E., Cohen, P., Tseng, A., Cagatay, T., Rathnasinghe, R., Flores, D., Jangra, S., Alam, F., Mena, N., Aslam, S., Saqi, A., Marin, A., Rutkowska, M., Ummadi, M. R., Pisanelli, G., Richardson, R. B., Veit, E. C., Fabius, J. M. A., Soucheray, M., Polacco, B. J., Evans, M. J., Swaney, D. L., Gonzalez-Reiche, A. S., Sordillo, E. M., van Bakel, H., Simon, V., Zuliani-Alvarez, L., Fontoura, B. M. A., Rosenberg, B. R., Krogan, N. J., Martinez-Sobrido, L., Garcia-Sastre, A., Miorin, L.
10.1101/2022.10.18.512708 — Posted: 2022-10-19
Regional epidemic dynamics and Delta variant diversity resulted in varying rates of spread of Omicron-BA.1 in Mexico
Zarate, S., Taboada, B., Rosales-Rivera, M., Garcia-Lopez, R., Munoz-Medina, J. E., Sanchez-Flores, A., Herrera-Estrella, A., Gomez-Gil, B., Mojica, N. S., Salas-Lais, A. G., Vazquez-Perez, J. A., Cabrera-Gaytan, D. A., Fernandes-Matano, L., Uribe-Noguez, L. A., Chale-Dzul, J. B., Maldonado Meza, B. I., Mejia-Nepomuceno, F., Perez-Padilla, R., Gutierrez-Rios, R. M., Loza, A., Lopez, S., Arias, C. F.
10.1101/2022.10.18.512746 — Posted: 2022-10-19
A collaborative approach to improving representation in viral genomic surveillance
Kim, P., Kim, A. Y., Newman, J. J., Cella, E., Bishop, T. C., Huwe, P. J., Uchakina, O. N., McKallip, R. J., Mack, V. L., Hill, M. P., Ogungbe, I. V., Adeyinka, O., Jones, S., Ware, G., Carroll, J. L., Sawyer, J. F., Densmore, K. H., Foster, M., Valmond, L., Thomas, J., Azarian, T., Queen, K., Kamil, J. P.
10.1101/2022.10.19.512816 — Posted: 2022-10-19
Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in Adults
Yassini, P., Hutchens, M., Paila, Y. D., Schoch, L., Aunins, A., Siangphoe, U., Paris, R.
10.1101/2022.10.18.22281050 — Posted: 2022-10-19
A spatio-temporal framework for modelling wastewater concentration during the COVID-19 pandemic
Li, G., Denise, H., Diggle, P., Grimsley, J., Holmes, C., James, D., Jersakova, R., Mole, C., Nicholson, G., Rangel Smith, C., Richardson, S., Rowe, W., Rowlingson, B., Torabi, F., Wade, M. J., Blangiardo, M.
10.1101/2022.10.14.22281081 — Posted: 2022-10-19
Effects of return-to-office, public schools reopening, and vaccination mandates on COVID-19 cases among municipal employee residents of New York City
Greene, S. K., Tabaei, B. P., Culp, G. M., Levin-Rector, A., Kishore, N., Baumgartner, J.
10.1101/2022.10.17.22280652 — Posted: 2022-10-19
Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants
Jittamala, P., Schilling, W. H. K., Watson, J. A., Luvira, V., Siripoon, T., Ngamprasertchai, T., Almeida, P. J., Ekkapongpisit, M., Cruz, C., Callery, J. J., Boyd, S., Anunsittichai, O., Hongsuwan, M., Singhaboot, Y., Pagornrat, W., Tuntipaiboontana, R., Kruabkontho, V., Ngernseng, T., Tubprasert, J., Abdad, M. Y., Keayarsa, S., Madmanee, W., Aguiar, R. S., Santos, F. M., Batty, E. M., Hanboonkunupakarn, P., Hanboonkunupakarn, B., Sookprome, S., Poovorawan, K., Imwong, M., Taylor, W. R., Chotivanich, V., Sangketchon, C., Ruksakul, W., Chotivanich, K., Pukrittayakamee, S., Dondorp, A. M., Day, N. P., Teixeira, M. M., Piyaphanee, W., Phumratanaprapin, W., White, N. J.
10.1101/2022.10.17.22281161 — Posted: 2022-10-19
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers
Schmidt, P., Narayan, K., Li, Y., Kaku, C., Brown, M., Champney, E., Geoghegan, J., Vasquez, M., Krauland, E., Yockachonis, T., Bai, S., Gunn, B., Cammarata, A., Rubino, C., Walker, L. M.
10.1101/2022.10.18.22281172 — Posted: 2022-10-19
Infection of primary nasal epithelial cells differentiates among lethal and seasonal human coronaviruses
Otter, C., Fausto, A., Tan, L. H., Cohen, N. A., Weiss, S. R.
10.1101/2022.10.17.512617 — Posted: 2022-10-18

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).